[ad_1]
“To approve a vaccine during a pandemic, it is necessary to have all the certainty and right now about the medicine AstraZeneca we are still working ”. So Armando Genazzani, Italian representative of the group that within theMother evaluates medications, was expressed in an interview with The impression about the much debated AstraZeneca vaccine. Genazzani assured that there is no delay, the dossier simply came after those of Pfizer (“which we authorize anticipating the evaluation in a week”) and Moderna (“in which we are intensely committed”).
Videos on this topic
“The vaccine uses a different technology than the previous two and is complex – explained to The impression -We have already evaluated the laboratory studies, we are analyzing the ingredients and how it is produced since 6-7 plants will be involved in different parts of the world that we need to operate in the same way ”. Then Genazzani clarified which are the main aspects that must necessarily be investigated before reaching the approval of the AstraZeneca serum: “This does not mean that there are problems but simply that there are situations to explore. For example, the fact that, unexpectedly, those who have been subjected to the administration of half a dose plus a subsequent one have greater protection than those who have received a whole dose plus a second. The studies have been carried out in several countries and the effectiveness varies: this also needs to be clarified. “So in conclusion it is unlikely that the approval will come before the end of January:” The deadline is that but we will do everything, as we have already demonstrated with the first dossier, to get ahead of the times ”, Genazzani assured.
[ad_2]
